Suppr超能文献

病例报告:瑞派替尼用于胃肠道间质瘤的新辅助治疗:一例病例报告

Case Report: Neoadjuvant therapy with ripretinib for gastrointestinal stromal tumor: a case report.

作者信息

Liu Guanmo, Zheng Zicheng, Li Jie, He Yixuan, Zhang Chenggang, Wang Yihua, Kang Weiming, Ye Xin

机构信息

Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

出版信息

Front Pharmacol. 2025 Apr 15;16:1573610. doi: 10.3389/fphar.2025.1573610. eCollection 2025.

Abstract

Neoadjuvant therapy targeting genotype-specific gastrointestinal stromal tumors (GISTs) may be indicated in select cases. While the majority of patients respond to Imatinib with a reduction in tumor size, some exhibit either poor response or resistance, necessitating the exploration of alternative therapeutic strategies. This report describes a high-risk patient facing potential multiorgan resections whose tumor responded poorly after 14 months of Imatinib therapy. After 8 months of transitioning to Ripretinib treatment, there was a 26% reduction in the largest tumor diameter. This improvement allowed better delineation of the tumor from the surrounding tissues, which in turn made it possible to perform an R0 resection while preserving the possibly involved organs. To our knowledge, this is the first case report of Ripretinib as a neoadjuvant therapy for GIST with peripheral organ invasion to achieve complete resection. This case report may present the effectiveness of Ripretinib and introduce a relatively novel approach to clinical treatment.

摘要

针对特定基因型胃肠道间质瘤(GIST)的新辅助治疗可能适用于某些特定病例。虽然大多数患者对伊马替尼有反应,肿瘤大小缩小,但有些患者反应不佳或耐药,因此需要探索替代治疗策略。本报告描述了一名面临潜在多器官切除的高危患者,其肿瘤在接受14个月伊马替尼治疗后反应不佳。在转为瑞派替尼治疗8个月后,最大肿瘤直径缩小了26%。这种改善使得肿瘤与周围组织的界限更清晰,进而有可能在保留可能受累器官的情况下进行R0切除。据我们所知,这是第一例将瑞派替尼作为新辅助治疗用于伴有外周器官侵犯的GIST以实现完全切除的病例报告。本病例报告可能展示了瑞派替尼的有效性,并引入了一种相对新颖的临床治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c3d/12037474/054b0609a4e3/fphar-16-1573610-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验